Q-omics provides the consensus-scored EFCAB6 profile across patient tissues and cancer cell-line models. EFCAB6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, EFCAB6 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, EFCAB6 RNA expression shows 19,494 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KICH, and KIRP as cancer lineages where EFCAB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB6 survival associations across molecular data types. EFCAB6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB6 RNA expression–survival associations across cancer types. High EFCAB6 expression shows favorable associations in UCEC, SCLC, KIRP, KIRC, ACC and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for EFCAB6 RNA expression.
This table summarizes EFCAB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EFCAB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB6 shows lower tumor expression in KICH, THCA, LUSC, LUAD and BRCA and higher tumor expression in CHOL. The KICH box plot shows higher EFCAB6 RNA expression in normal versus tumor tissue (log2 FC = −0.930, t-test p < 0.001).
This table shows molecular features associated with EFCAB6 in patient tissues and cancer cell lines. In patient samples, EFCAB6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, EFCAB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
